Enhanced brain penetration of hexamethonium in complexes with derivatives of fullerene C60

Abstract

The present report describes development of hexamethonium complexes based on fullerene C₆₀. Hexamethonium has a limited penetration into CNS and therefore can antagonize central effects of nicotine only when given at high doses. In the present studies conducted in laboratory rodents, intraperitoneal administration of hexamethonium-fullerene complexes blocked effects of nicotine (convulsions and locomotor stimulation). When compared to equimolar doses of hexamethonium, complexes of hexamethonium with derivatives of fullerene C₆₀ were 40 times more potent indicating an enhanced ability to interact with central nicotine receptors. Thus, fullerene C₆₀ derivatives should be explored further as potential carrier systems for polar drug delivery into CNS.